Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

被引：1

作者：

Harrison, Claire N. ^{[1
]}

Schaap, Nicolaas ^{[2
]}

Vannucchi, Alessandro M. ^{[3
]}

Kiladjian, Jean-Jacques ^{[4
]}

Jourdan, Eric ^{[5
]}

Silver, Richard T. ^{[6
]}

Schouten, Harry C. ^{[7
]}

Passamonti, Francesco ^{[8
]}

Zweegman, Sonja ^{[9
]}

Talpaz, Moshe ^{[10
]}

Verstovsek, Srdan ^{[11
]}

Rose, Shelonitda ^{[12
]}

Tang, Derek ^{[12
]}

Hu, Angela ^{[12
]}

Guo, Shien ^{[13
]}

Liao, Weiqin ^{[13
]}

Brownstein, Carrie ^{[14
]}

Mesa, Ruben A. ^{[15
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, Dept Clin Haematol, London, England

[2] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands

[3] Univ Florence, AOU Careggi, Florence, Italy

[4] Hop St Louis, Paris, France

[5] Inst Cancerol Gard, Hematol Clin, Nimes, France

[6] Weill Cornell Med Coll, New York, NY USA

[7] Univ Hosp Maastricht, Dept Internal Med Hematol, Maastricht, Netherlands

[8] Univ Insubria, Dept Med & Surg, Varese, Italy

[9] Vrije Univ Amsterdam, Amsterdam UMC, Dept Hematol, Amsterdam, Netherlands

[10] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[12] Celgene Corp, Summit, NJ USA

[13] Evidera, Waltham, MA USA

[14] Celgene Corp, Summit, NJ USA

[15] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-129386

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2207

引用

页数：5

共 50 条

[41] Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy
Chari, Ajai
Munder, Markus
Weisel, Katja
Jenner, Matthew
Bygrave, Ceri
Petrucci, Maria Teresa
Boccadoro, Mario
Cavo, Michele
van de Donk, Niels W. C. J.
Turgut, Mehmet
Demirkan, Fatih
Karadogan, Ihsan
Libby, Edward
Kleiman, Robert
Kuppens, Steven
Bandekar, Rajesh
Neff, Tobias
Heuck, Christoph
Qi, Ming
Clemens, Pamela L.
Goldschmidt, Hartmut
ADVANCES IN THERAPY, 2021, 38 (02) : 1328 - 1341
[42] The MD Anderson Cancer Center (MDACC) Experience with Ruxolitinib, An Oral JAK1 and JAK2 Inhibitor, in Myelofibrosis: Long-Term Follow-up Outcomes of 107 Patients From a Phase I/II Study
Verstovsek, Srdan
Estrov, Zeev
Cortes, Jorge E.
Thomas, Deborah A.
Borthakur, Gautam
Kadia, Tapan
Jabbour, Elias
Pierce, Sherry
Kantarjian, Hagop M.
BLOOD, 2011, 118 (21) : 1646 - 1646
[43] Health related quality of life (HRQOL) in patients with ulcerative colitis (UC) treated with obefazimod: the phase 2 open label maintenance study
Vermeire, S.
Sands, B. E.
Rabbat, C.
Shan, K.
Dolan, C. M.
Cataldi, F.
Jacobstein, D.
Fine, J. T.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1604 - I1604
[44] A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis
Lebedinsky, Claudia
Anthony, Stephen P.
Mohi, Golam
Yang, Huyuan
Mei, Jian
Braendle, Edgar
BLOOD, 2020, 136
[45] Safety and Efficacy of Fedratinib, an Oral, Selective JAK2 Inhibitor, in Patients with Polycythemia Vera (PV) Resistant or Intolerant to Hydroxyurea: Results from a Phase II Dose-Ranging and Dose-Expansion Study
Pardanani, Animesh
Harrison, Claire
Vannucchi, Alessandro
Shortt, Jake
Kiladjian, Jean-Jacques
Martinelli, Giovanni
Rose, Shelonitda
Zhang, Jun
Tefferi, Ayalew
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S332 - S333
[46] Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b
Brandberg, Y.
Aamdal, S.
Bastholt, L.
Hernberg, M.
Stierner, U.
von der Maase, H.
Hansson, J.
EUROPEAN JOURNAL OF CANCER, 2012, 48 (13) : 2012 - 2019
[47] A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)
Mascarenhas, John
Harrison, Claire N.
Kiladjian, Jean-Jacques
Komrokji, Rami S.
Koschmieder, Steffen
Vannucchi, Alessandro
Berry, Tymara
Sherman, Laurie
Dougherty, Souria
Sun, Libo
Huang, Fei
Wan, Ying
Feller, Faye
Rizo, Aleksandra
Verstovsek, Srdan
BLOOD, 2021, 138
[48] Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial
Mascarenhas, John O.
Harrison, Claire
Bose, Prithviraj
Kiladjian, Jean-Jacques
Lucchesi, Alessandro
Vannucchi, Alessandro Maria
Berry, Tymara
Riggs, Jennifer
Peng, Lixian
Huang, Fei
Wan, Ying
Rodolf, Vivian
Ho, Judy
Navada, Shyamala
Komrokji, Rami S.
BLOOD, 2024, 144 : 18081 - 18083
[49] MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
Mascarenhas, John
Harrison, Claire
Kiladjian, Jean-Jacques
Komrokji, Rami S.
Koschmieder, Steffen
Vannucchi, Alessandro M.
Berry, Tymara
Redding, Denise
Sherman, Laurie
Dougherty, Souria
Peng, Lixian
Sun, Libo
Huang, Fei
Wan, Ying
Feller, Faye
Verstovsek, Srdan
BLOOD, 2022, 140 : 6826 - 6829
[50] Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-BEACON Study
Genovese, Mark
Kremer, Joel
Zamani, Omid
Ludivico, Charles
Krogulec, Marek
Xie, Li
Beattie, Scott
Koch, Alisa
Cardillo, Tracy
Rooney, Terence
Macias, William
Schlichting, Douglas
Smolen, Josef
Bookman, Arthur
JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1188 - 1188

← 1 2 3 4 5 →